Beta Bionics officer plans $101,919 stock sale

An officer of Beta Bionics filed a Rule 144 notice to potentially sell 5,300 BBNX common shares valued at about $101,919.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) officer Michael Mensinger has filed a notice under Rule 144 to potentially dispose of 5,300 shares of common stock of Beta Bionics through Morgan Stanley Smith Barney LLC on or after September 16, 2026. The filing states an aggregate market value of about $101,919 for these shares. The shares to be sold were acquired by a Series D purchase on September 12, 2023 (5,107 shares) and by exercise of warrants on January 30, 2025 (193 shares). The notice also reports that Mensinger sold 4,375 shares of common stock for $83,619.81 on September 2, 2026.

Key Figures

Shares to be sold: 5,300 shares Aggregate market value of shares to be sold: $101,919.00 Shares sold in past 3 months: 4,375 shares +3 more

6 metrics

Shares to be sold 5,300 shares Common stock covered by the Rule 144 notice

Aggregate market value of shares to be sold $101,919.00 Value of 5,300 shares listed in the Rule 144 filing

Shares sold in past 3 months 4,375 shares Common stock sold on September 2, 2026

Proceeds from past 3-month sale $83,619.81 Total consideration for 4,375 shares sold on September 2, 2026

Shares from Series D purchase 5,107 shares Common stock acquired on September 12, 2023

Shares from warrant exercise 193 shares Common stock acquired on January 30, 2025

Key Terms

Rule 144, Series D Purchase, Exercised of Warrants, Securities To Be Sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Series D Purchase financial

"Common | 09/12/2023 | Series D Purchase | Issuer"

Exercised of Warrants financial

"Common | 01/30/2025 | Exercised of Warrants | Issuer"

Securities To Be Sold financial

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for BBNX?

It discloses that officer Michael Mensinger may sell 5,300 shares of Beta Bionics common stock under Rule 144, with an aggregate market value of about $101,919, through Morgan Stanley Smith Barney LLC on or after September 16, 2026.

How many Beta Bionics (BBNX) shares are covered by this Form 144?

The notice covers a potential sale of 5,300 shares of common stock of Beta Bionics, Inc. The filing lists these shares with an aggregate market value of approximately $101,919 as of the date referenced.

How did the filer acquire the BBNX shares to be sold under Rule 144?

The filing states that 5,107 shares were acquired via a Series D purchase on September 12, 2023, and 193 shares were acquired by exercise of warrants on January 30, 2025, totaling the 5,300 shares covered.

What recent sales of Beta Bionics (BBNX) stock does the Form 144 report?

The notice reports that Michael Mensinger sold 4,375 shares of Beta Bionics common stock on September 2, 2026 for total proceeds of $83,619.81 during the past three months.

Through which broker will the BBNX Rule 144 sale be executed?

The potential sale of 5,300 Beta Bionics common shares is listed as being through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY, as the broker handling the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:40 PM Accepted by SEC EDGAR 09/16/2026 - 04:40 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002048500
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BETA BIONICS, INC.
SEC File Number	001-42491
Address of Issuer	11 Hughes Irvine CALIFORNIA 92618
Phone	9494277785
Name of Person for Whose Account the Securities are To Be Sold	MICHAEL MENSINGER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5300	101919.00	44989688	09/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/12/2023	Series D Purchase	Issuer			5107	09/12/2023	Cash
Common	01/30/2025	Exercised of Warrants	Issuer			193	01/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MICHAEL MENSINGER 11 Hughes Irvine CA 92618	Common	09/02/2026	4375	83619.81

144: Remarks and Signature

Remarks
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Michael Mensinger
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)